Understanding Hypertriglyceridemia: Integrating Genetic Insights

Area of Science:

• Genetics
• Metabolic Disorders
• Cardiovascular Health

Background:

• Hypertriglyceridemia involves elevated plasma triglycerides, raising risks for acute pancreatitis and cardiovascular diseases.
• Phenotype expression is heterogeneous, influenced by obesity, alcohol, and metabolic syndromes.

Purpose of the Study:

• Review genetic variants in triglyceride-regulating genes (LPL, APOA5, APOC2, GPIHBP1, LMF1).
• Discuss monogenic and polygenic hypertriglyceridemia.
• Address advancements in triglyceride-lowering treatments.

Main Methods:

• Focus on genetic variants in five canonical triglyceride-regulating genes.
• Categorize hypertriglyceridemia as monogenic (familial chylomicronemia syndrome) or polygenic (multifactorial chylomicronemia syndrome).
• Review current triglyceride-lowering therapies.

Main Results:

• Pathogenic variants in LPL, APOA5, APOC2, GPIHBP1, and LMF1 disrupt triglyceride-rich lipoprotein metabolism.
• Monogenic forms result from homozygous/compound heterozygous variants; polygenic forms involve heterozygous variants and polymorphisms.
• Genetic understanding offers new avenues for screening and therapies.

Conclusions:

• Genetic factors significantly contribute to hypertriglyceridemia.
• Identifying genetic variants is crucial for personalized risk assessment and treatment.
• Further research into genetic underpinnings will drive novel therapeutic development.